ABBV vs DDOG: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Datadog, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-25.
AbbVie Inc. · Healthcare
$261.70
-1.0% upside to fair value
Med Conviction
Grade C
High Quality
VS
Datadog, Inc. · Technology
$256.92
+28.7% upside to fair value
Med Conviction
Grade C
High Quality
QuantHub Verdict
DDOG has more upside to fair value
(+28.7%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
DDOG |
| Current Price |
$261.70 |
$256.92 |
| Fair Value Estimate |
$259.04 |
$330.72 |
| Upside to Fair Value |
-1.0%
|
+28.7%
|
| Market Cap |
$462.4B |
$91.5B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
24.8x
|
350.6x
|
| Price / Sales |
7.2x
|
23.1x
|
| Price / FCF |
23.6x
|
78.9x
|
| Revenue Growth YoY |
+10.2%
|
+35.6%
|
| Gross Margin |
71.5%
|
79.5%
|
| Operating Margin |
29.3%
|
0.4%
|
| Return on Equity |
-136.5%
|
4.6%
|
| Dividend Yield |
2.61% |
0% |
| FCF Yield |
4.25%
|
1.27%
|
| Analyst Consensus |
Strong Buy
|
Strong Buy
|
Investment Thesis
AbbVie is a diversified branded-biopharma company spanning immunology, neuroscience, oncology and aesthetics, with high-margin TTM economics including a 71.5% gross margin and 29.3% operating margin. Its successor immunology franchises are performing strongly: Q2 2026 revenue rose 10.2% year over year, with Skyrizi up 24.4% to $5.505 billion and Rinvoq up 24.5% to $2.525 billion, helping offset a…
Datadog is a cloud observability platform that unifies infrastructure monitoring, application performance management, log management, security, and incident response into a single SaaS offering used by developers and IT operations teams across North America and internationally. The business quality is high on the top line: revenue grew 35.6% year over year in the most recent quarter, TTM gross ma…
Accumulation Zones
| Metric |
ABBV |
DDOG |
| Zone Low |
$194.28 |
$248.04 |
| Zone High |
$220.18 |
$281.11 |
| In Buy Zone? |
No
|
Yes
|